1240494-13-6
1240494-13-6
Chemical Structure
SX-517
- CAS No.: 1240494-13-6
- Formula:C19H16BFN2O3S
- Molecular Weight:382.22
IUPAC Name: (2-(((5-((4-fluorophenyl)carbamoyl)pyridin-2-yl)thio)methyl)phenyl)boronic acid
InChIKey: VZRIHFZJVIOJBE-UHFFFAOYSA-N
SMILES: OB(C1=CC=CC=C1CSC2=NC=C(C(NC3=CC=C(F)C=C3)=O)C=C2)O
Biological Activity: SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca2+ flux (IC50=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SX-517 | 99.90% | SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca2+ flux (IC50=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. J Med Chem. 2014 Oct 23;57(20):8378-97. [Content Brief]
- [2]. Ti H, et al. Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). J Med Chem. 2019 Jul 11;62(13):5944-5978. [Content Brief]
